Report topline data from the Phase 3 ACTIVATE-T study
Delivered after the deadline (70 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- 9 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Report topline data from the Phase 3 ACTIVATE-T study of mitapivat in adults with PK deficiency who receive regular transfusions in the first quarter of 2021”
What we found
Evidence strength A What the grades mean
The company reported topline data for the ACTIVATE-T study in June 2021, which occurred after the first quarter 2021 deadline.
-
A Agios Pharmaceuticals, Inc. 8-K filed 2021-04-29
“Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress” ✓ confirmed on the page
-
A Agios Pharmaceuticals, Inc. 10-Q filed 2021-11-03
“We reported in June 2021, in a full analysis of updated data, that this trial met its primary endpoint” ✓ confirmed on the page
Market reaction: the shares moved -9.7% against the S&P 500 over the three sessions around the disclosure (2 Nov 2021 to 5 Nov 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Topline data from Phase 3 ACTIVATE-T study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Agios Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AGIO-021572 · Corrections policy